STAT Plus: Watchdog scolds HHS for lacking a big-picture plan to incentivize antibiotic development
Amid growing anxiety over a lack of antibiotics, a new report from a Congressional watchdog found that the Department of Health and Human Services lacks an overarching strategy for developing new incentives to manufacturers.
In particular, the Government Accountability Office argued in a new report that HHS so far hasn’t agreed about the need to offer certain types of so-called pull incentives, which could be offered to companies to help cover manufacturing and marketing costs after antibiotics have been approved by the Food and Drug Administration and reached the market.
